California Stem Cell Inc. Files IND to Commence Phase I Clinical Trial in Spinal Muscular Atrophy
FSMA Press Release | December 1, 2010
IRVINE, Calif. (December 1, 2010) – California Stem Cell, Inc. (CSC) and Families of Spinal Muscular Atrophy (FSMA) announced today that CSC has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for approval to commence a Phase I safety study on a jointly-developed stem cell-derived motor neuron transplantation therapy for Spinal Muscular Atrophy (SMA) Type I.
Click HERE or on the image below to read more…
Posted by stronwi 
SMAHeadlines.com 